Praxis Precision Medicines Files 8-K

Ticker: PRAX · Form: 8-K · Filed: Sep 3, 2024 · CIK: 1689548

Praxis Precision Medicines, Inc. 8-K Filing Summary
FieldDetail
CompanyPraxis Precision Medicines, Inc. (PRAX)
Form Type8-K
Filed DateSep 3, 2024
Risk Levellow
Pages3
Reading Time4 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: corporate-disclosure, 8-K

TL;DR

Praxis Precision Medicines filed an 8-K on Sept 3rd. Standard corporate update.

AI Summary

Praxis Precision Medicines, Inc. filed an 8-K on September 3, 2024, to report on various corporate events. The filing includes information related to Regulation FD disclosures, other events, and financial statements and exhibits. The company is incorporated in Delaware and headquartered in Boston, Massachusetts.

Why It Matters

This 8-K filing provides important updates and disclosures from Praxis Precision Medicines, Inc. to investors and the public.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new risks.

Key Players & Entities

  • Praxis Precision Medicines, Inc. (company) — Registrant
  • September 3, 2024 (date) — Date of earliest event reported
  • Delaware (jurisdiction) — State of incorporation
  • Boston, Massachusetts (location) — Principal executive offices

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report on Regulation FD disclosures, other events, and financial statements and exhibits for Praxis Precision Medicines, Inc.

When was the earliest event reported in this filing?

The earliest event reported in this filing occurred on September 3, 2024.

Where is Praxis Precision Medicines, Inc. headquartered?

Praxis Precision Medicines, Inc. is headquartered at 99 High Street, 30th Floor, Boston, Massachusetts 02110.

In which state is Praxis Precision Medicines, Inc. incorporated?

Praxis Precision Medicines, Inc. is incorporated in Delaware.

What is the company's SIC code?

The company's Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 1,016 words · 4 min read · ~3 pages · Grade level 12.1 · Accepted 2024-09-03 08:15:48

Key Financial Figures

  • $0.0001 — e on which registered Common Stock, $0.0001 par value per share PRAX The Nasdaq

Filing Documents

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On September 3, 2024, Praxis Precision Medicines, Inc. (the "Company") published a corporate presentation announcing topline results from its EMBOLD Study. The presentation is available in the "Investors + Media" portion of the Company's website at investors.praxismedicines.com and a copy is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01 of this Form 8-K and Exhibit 99.1 attached hereto shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall any of it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01. Other Events

Item 8.01. Other Events. On September 3, 2024, the Company announced topline results from the EMBOLD study evaluating relutrigine (PRAX-562) in SCN2A and SCN8A developmental and epileptic encephalopathy (DEE) patients. EMBOLD is a multicenter, double-blind, placebo-controlled, intervention-period-masked, randomized study, followed by open-label extension (OLE), which enrolled eligible male and female participants aged 2-18 years with a diagnosis of early onset SCN2A -DEE or SCN8A -DEE. Sixteen patients were randomized (1:1) to receive relutrigine QD for 16 weeks, or relutrigine QD for 12 weeks and matching placebo QD for 4 weeks, administered orally or via gastrostomy/jejunostomy tube (G/J-tube). Fifteen patients were determined to be eligible for efficacy assessments. Dose adjustment was permitted to a maximum of 1.0 mg/kg/day and a minimum of 0.25 mg/kg/day. Thirteen patients enrolled in the OLE. Summary of EMBOLD results Relutrigine was generally safe and well tolerated by patients during the EMBOLD study. Seven patients increased the daily dose from 0.5 to 1 mg/kg/day during the double-blind period of the study. No patient required dose reduction. The most common adverse events (AE) were infections, vomiting, pyrexia, somnolence and constipation in patients receiving relutrigine. No patients discontinued due to an AE. Patients on relutrigine observed a placebo-adjusted reduction of 46% in countable motor seizures (log-transformed). Change in Global Impression of Improvement, assessed by the caregiver and clinician at week 16 for patients on relutrigine, showed an improvement (caregiver, clinician) in disruptive behavior (29%, 23%), communication (43%, 31%), seizure severity and intensity (71%, 62%) and alertness (57%, 69%). Eight patients have completed at least one 28-day period in the long-term extension of EMBOLD with a median reduction in motor seizures of 75%. Five patients achieved a 28-day seizure free status while receiving relutrigine, compared

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the clinical development of relutrigine, including with respect to the EMBOLD and related long-term extension study, and the potential benefits of relutrigine to treat patients aged 2-18 years with a diagnosis of early onset SCN2A-DEE or SCN8A-DEE. The forward-looking statements included in this Current Report on Form 8-K are subject to a number of risks, uncertainties and assumptions, including, without limitation, uncertainties inherent in clinical trials, the expected timing of submission for regulatory approval or review by governmental authorities and other risks as described in the Company's Annual Report on Form 10-K for the year ended December 31, 2023 and its other filings with the Securities and Exchange Commission. These statements are based only on facts currently known by the Company and speak only as of the date of this Current Report on Form 8-K. As a result, you are cautioned not to rely on these forward-looking statements and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 EMBOLD Corporate Presentation 104 Cover Page Interactive Data File (embedded within the inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PRAXIS PRECISION MEDICINES, INC. Date: September 3, 2024 By: /s/ Marcio Souza Marcio Souza Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.